Cargando…

Prognostic value of low muscle mass at the 12(th) thoracic vertebral level in multiple myeloma treated with transplantation: CAREMM-2101 study

PURPOSE: Autologous hematopoietic stem cell transplantation (ASCT) has been introduced as a standard treatment for newly diagnosed multiple myeloma (NDMM) following novel agent-based induction chemotherapy. This study investigated whether pre-ASCT low muscle mass evaluated using the paraspinal muscl...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Sung-Soo, Kwag, Daehun, Lee, Jung Yeon, Jeon, Young-Woo, Yahng, Seung-Ah, Shin, Seung-Hwan, Youn, Seo Yeon, Min, Chang-Ki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Galenos Publishing 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10679641/
https://www.ncbi.nlm.nih.gov/pubmed/37312491
http://dx.doi.org/10.4274/dir.2023.232097
_version_ 1785150618056261632
author Park, Sung-Soo
Kwag, Daehun
Lee, Jung Yeon
Jeon, Young-Woo
Yahng, Seung-Ah
Shin, Seung-Hwan
Youn, Seo Yeon
Min, Chang-Ki
author_facet Park, Sung-Soo
Kwag, Daehun
Lee, Jung Yeon
Jeon, Young-Woo
Yahng, Seung-Ah
Shin, Seung-Hwan
Youn, Seo Yeon
Min, Chang-Ki
author_sort Park, Sung-Soo
collection PubMed
description PURPOSE: Autologous hematopoietic stem cell transplantation (ASCT) has been introduced as a standard treatment for newly diagnosed multiple myeloma (NDMM) following novel agent-based induction chemotherapy. This study investigated whether pre-ASCT low muscle mass evaluated using the paraspinal muscle index (PMI) at the 12(th) thoracic vertebra (T12) level is a reliable prognostic marker in NDMM after chemotherapy. METHODS: A multi-center registry database was retrospectively analyzed. Between 2009 and 2020, 190 patients with chest computed tomography images underwent frontline ASCT following induction therapy. The PMI was defined as the value of the paraspinal muscle area at the T12 level divided by the square of the patient’s height. The cut-off value indicating a low muscle mass was sex-specific, using the lowest quintiles. RESULTS: Of the 190 patients, 38 (20%) were in the low muscle mass group. The low muscle mass group had a lower 4-year overall survival (OS) rate than the non-low muscle mass group (68.5% vs. 81.2%; P = 0.074). The median progression-free survival (PFS) in the low muscle mass group was significantly shorter compared with the non-low muscle mass group (23.3 months vs. 29.2 months; P = 0.029). The cumulative incidence of transplant-related mortality (TRM) was significantly higher in the low muscle mass group than in the non-low muscle mass group (4-year probability of TRM incidence, 10.6% vs. 0.7%; P < 0.001). In contrast, no significant difference in the cumulative incidence of disease progression was found between the two groups. Multivariate analysis revealed that low muscle mass was associated with significant negative outcomes for OS [(hazard ratio (HR): 2.14; P = 0.047], PFS (HR: 1.78; P = 0.012), and TRM (HR: 12.05; P = 0.025). CONCLUSION: Paraspinal muscle mass may have a prognostic role in NDMM patients who undergo ASCT. Patients with low paraspinal muscle mass have lower survival outcomes compared to non-low muscle mass group.
format Online
Article
Text
id pubmed-10679641
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Galenos Publishing
record_format MEDLINE/PubMed
spelling pubmed-106796412023-12-05 Prognostic value of low muscle mass at the 12(th) thoracic vertebral level in multiple myeloma treated with transplantation: CAREMM-2101 study Park, Sung-Soo Kwag, Daehun Lee, Jung Yeon Jeon, Young-Woo Yahng, Seung-Ah Shin, Seung-Hwan Youn, Seo Yeon Min, Chang-Ki Diagn Interv Radiol General Radiology - Original Article PURPOSE: Autologous hematopoietic stem cell transplantation (ASCT) has been introduced as a standard treatment for newly diagnosed multiple myeloma (NDMM) following novel agent-based induction chemotherapy. This study investigated whether pre-ASCT low muscle mass evaluated using the paraspinal muscle index (PMI) at the 12(th) thoracic vertebra (T12) level is a reliable prognostic marker in NDMM after chemotherapy. METHODS: A multi-center registry database was retrospectively analyzed. Between 2009 and 2020, 190 patients with chest computed tomography images underwent frontline ASCT following induction therapy. The PMI was defined as the value of the paraspinal muscle area at the T12 level divided by the square of the patient’s height. The cut-off value indicating a low muscle mass was sex-specific, using the lowest quintiles. RESULTS: Of the 190 patients, 38 (20%) were in the low muscle mass group. The low muscle mass group had a lower 4-year overall survival (OS) rate than the non-low muscle mass group (68.5% vs. 81.2%; P = 0.074). The median progression-free survival (PFS) in the low muscle mass group was significantly shorter compared with the non-low muscle mass group (23.3 months vs. 29.2 months; P = 0.029). The cumulative incidence of transplant-related mortality (TRM) was significantly higher in the low muscle mass group than in the non-low muscle mass group (4-year probability of TRM incidence, 10.6% vs. 0.7%; P < 0.001). In contrast, no significant difference in the cumulative incidence of disease progression was found between the two groups. Multivariate analysis revealed that low muscle mass was associated with significant negative outcomes for OS [(hazard ratio (HR): 2.14; P = 0.047], PFS (HR: 1.78; P = 0.012), and TRM (HR: 12.05; P = 0.025). CONCLUSION: Paraspinal muscle mass may have a prognostic role in NDMM patients who undergo ASCT. Patients with low paraspinal muscle mass have lower survival outcomes compared to non-low muscle mass group. Galenos Publishing 2023-07-20 /pmc/articles/PMC10679641/ /pubmed/37312491 http://dx.doi.org/10.4274/dir.2023.232097 Text en © Copyright 2023 by Turkish Society of Radiology | Diagnostic and Interventional Radiology, published by Galenos Publishing House. https://creativecommons.org/licenses/by-nc/4.0/Content of this journal is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. (https://creativecommons.org/licenses/by-nc/4.0/)
spellingShingle General Radiology - Original Article
Park, Sung-Soo
Kwag, Daehun
Lee, Jung Yeon
Jeon, Young-Woo
Yahng, Seung-Ah
Shin, Seung-Hwan
Youn, Seo Yeon
Min, Chang-Ki
Prognostic value of low muscle mass at the 12(th) thoracic vertebral level in multiple myeloma treated with transplantation: CAREMM-2101 study
title Prognostic value of low muscle mass at the 12(th) thoracic vertebral level in multiple myeloma treated with transplantation: CAREMM-2101 study
title_full Prognostic value of low muscle mass at the 12(th) thoracic vertebral level in multiple myeloma treated with transplantation: CAREMM-2101 study
title_fullStr Prognostic value of low muscle mass at the 12(th) thoracic vertebral level in multiple myeloma treated with transplantation: CAREMM-2101 study
title_full_unstemmed Prognostic value of low muscle mass at the 12(th) thoracic vertebral level in multiple myeloma treated with transplantation: CAREMM-2101 study
title_short Prognostic value of low muscle mass at the 12(th) thoracic vertebral level in multiple myeloma treated with transplantation: CAREMM-2101 study
title_sort prognostic value of low muscle mass at the 12(th) thoracic vertebral level in multiple myeloma treated with transplantation: caremm-2101 study
topic General Radiology - Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10679641/
https://www.ncbi.nlm.nih.gov/pubmed/37312491
http://dx.doi.org/10.4274/dir.2023.232097
work_keys_str_mv AT parksungsoo prognosticvalueoflowmusclemassatthe12ththoracicvertebrallevelinmultiplemyelomatreatedwithtransplantationcaremm2101study
AT kwagdaehun prognosticvalueoflowmusclemassatthe12ththoracicvertebrallevelinmultiplemyelomatreatedwithtransplantationcaremm2101study
AT leejungyeon prognosticvalueoflowmusclemassatthe12ththoracicvertebrallevelinmultiplemyelomatreatedwithtransplantationcaremm2101study
AT jeonyoungwoo prognosticvalueoflowmusclemassatthe12ththoracicvertebrallevelinmultiplemyelomatreatedwithtransplantationcaremm2101study
AT yahngseungah prognosticvalueoflowmusclemassatthe12ththoracicvertebrallevelinmultiplemyelomatreatedwithtransplantationcaremm2101study
AT shinseunghwan prognosticvalueoflowmusclemassatthe12ththoracicvertebrallevelinmultiplemyelomatreatedwithtransplantationcaremm2101study
AT younseoyeon prognosticvalueoflowmusclemassatthe12ththoracicvertebrallevelinmultiplemyelomatreatedwithtransplantationcaremm2101study
AT minchangki prognosticvalueoflowmusclemassatthe12ththoracicvertebrallevelinmultiplemyelomatreatedwithtransplantationcaremm2101study